Cancer risk in women receiving estrogen-progestin replacement therapy.

摘要: Abstract Objectives and methods: The epidemiological literature was reviewed in order to evaluate the relationship between hormone replacement therapy risk of cancer breast reproductive organs. Results: For cancer, there is no evidence an overall increase risk. According several studies, but not all, duration intake seems affect Many years both estradiol compounds conjugated estrogens can be assumed 1.5-2-fold. addition progestins does seem alter (reduce) duration-risk relationship. magnitude likely small may explained partly by methodological problems, or differences study populations. prognosis patients with HRT-related more favourable than for non-exposed patients. Because importance issue, inconsistencies results, further research urgent. Especially, urgent need define sub-groups women who would susceptible adverse influence HRT. Regarding endometrial a duration-dependent strong long-term only established. level about 10-fold after 10 intake, that decrease discontinuation treatment. Added at least days per cycle reduce eliminate increase. Tumors occurring estrogen have biological characteristics. Future will needed safety various progestin regimens. Ovarian affected Available data are inconsistent contradictory. Due pronounced protective effect oral contraceptives, measure effects estrogen-progestin combined Cervical has been shown Conclusions: It concluded therapy, alone progestins, important on particularly endometrium. Therefore, when making risk-benefit assessment HRT, possible relationships should considered.